Latest Conference Articles

December 14th 2019, 1:22am

San Antonio Breast Cancer Symposium

Residual cancer burden after neoadjuvant chemotherapy has been shown to be an accurate long-term predictor of disease recurrence and survival across all breast cancer subtypes.

December 13th 2019, 11:39pm

San Antonio Breast Cancer Symposium

The addition of encequidar (HM30181A) to oral paclitaxel is the first oral taxane regimen to result in an improvement in overall response rates as compared with an intravenous administration of paclitaxel in patients with metastatic breast cancer.

December 13th 2019, 11:28pm

San Antonio Breast Cancer Symposium

Estrogen alone as menopausal hormone therapy was found to decrease breast cancer incidence in postmenopausal women.

December 13th 2019, 11:05pm

San Antonio Breast Cancer Symposium

Karen Pinilla Alba, MD, discusses the safety findings stages 1 and 2 of the phase II/III PARTNER trial in triple negative and/or germline BRCA-mutated breast cancer.

December 13th 2019, 6:07pm

San Antonio Breast Cancer Symposium

A durvalumab-based neoadjuvant regimen induced an impressive pathologic complete response rate in patients with triple-negative breast cancer.

December 13th 2019, 6:27am

San Antonio Breast Cancer Symposium

Nancy Lin, MD, discusses the impact of neratinib on development and progression of central nervous system metastases in patients with HER2-positive metastatic breast cancer.

December 13th 2019, 6:25am

San Antonio Breast Cancer Symposium

Pierfranco Conte, MD, discusses the findings of the OlympiAD trial in BRCA-mutated HER2-negative metastatic breast cancer.

December 13th 2019, 3:12am

San Antonio Breast Cancer Symposium

Accelerated partial breast irradiation using intensity-modulated radiotherapy is not significantly different from whole breast irradiation in preventing recurrence in patients with low-risk early breast cancer.

December 13th 2019, 3:07am

San Antonio Breast Cancer Symposium

Olaparib continued to show a numerical overall survival (OS) benefit with a favorable hazard ratio for OS versus chemotherapy in patients with BRCA-positive, HER2-negative metastatic breast cancer, according to an extended, exploratory follow-up analysis of the phase III OlympiAD trial.

December 13th 2019, 2:37am

San Antonio Breast Cancer Symposium

A pathologic complete response to HER2-directed neoadjuvant therapy reduced the risk of recurrence in early HER2-positive breast cancer but did not eliminate it, supporting the common practice of continued anti-HER2 therapy.

December 13th 2019, 2:11am

San Antonio Breast Cancer Symposium

Atezolizumab (Tecentriq) in combination with carboplatin and nab-paclitaxel (Abraxane) did not lead to a statistically significant increase in pathologic complete response (pCR) rate compared with carboplatin/nab-paclitaxel alone in patients with early high-risk and locally advanced triple-negative breast cancer,

December 13th 2019, 12:11am

San Antonio Breast Cancer Symposium

Maintenance durvalumab may improve outcomes versus chemotherapy in patients with triple-negative breast cancer or those with PD-L1–positive breast cancer across several subtypes, according to exploratory analyses from the phase II randomized SAFIR02-IMMUNO trial presented at the 2019 San Antonio Breast Cancer Symposium.

December 12th 2019, 11:51pm

San Antonio Breast Cancer Symposium

The aromatase inhibitor anastrozole maintained a preventive effect for postmenopausal women at high risk for breast cancer nearly 12 years after discontinuing treatment.

December 12th 2019, 10:53pm

San Antonio Breast Cancer Symposium

Patients with triple-negative breast cancer have greater rates of pathologic complete responses when pembrolizumab is added to neoadjuvant and adjuvant chemotherapy. Furthermore, these benefits are observed across patient subgroups, most notably in those patients with stage III and/or node-positive disease.

December 12th 2019, 9:50am

San Antonio Breast Cancer Symposium

Real-world data for frontline palbociclib indicate that the positive progression-free survival data observed with the CDK4/6 inhibitor in the pivotal PALOMA-2 trial would likely translate to an overall survival benefit in patients with HR-positive/HER2-negative metastatic breast cancer

December 12th 2019, 6:03am

San Antonio Breast Cancer Symposium

Rashmi K. Murthy, MD, MBE, discusses results of the HER2CLIMB trial in previously treated HER2-positive breast cancer.

December 12th 2019, 5:24am

San Antonio Breast Cancer Symposium

Sara A. Hurvitz, MD, associate professor of medicine and medical oncologist, University of California Los Angeles, discusses the use of antibody-drug conjugates in HER2-positive breast cancer.

December 12th 2019, 4:49am

San Antonio Breast Cancer Symposium

The first reported data for adjuvant ado-trastuzumab emtansine in early HER2-positive breast cancer showed high rates of disease control in a randomized trial designed to compare toxicities with trastuzumab and paclitaxel.

December 12th 2019, 3:52am

San Antonio Breast Cancer Symposium

Margetuximab continued to show a clear progression-free survival benefit and a trend toward an overall survival benefit versus trastuzumab (Herceptin) when either agent was combined with chemotherapy in patients with HER2-positive metastatic breast cancer who had received prior anti-HER2 therapies.

December 12th 2019, 1:50am

San Antonio Breast Cancer Symposium

Adjuvant pertuzumab (Perjeta) with trastuzumab (Herceptin) plus chemotherapy showed a 0.9% improvement in overall survival and continued to reduce the risk of disease recurrence in patients with HER2-positive early breast cancer.